← Leaderboards
Steven H Olson
Sanford Burnham Prebys Medical Discovery Institute
$9,813,239
Attributed
$17,693,029
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,693,029 · 9
By mechanism
R01$16,687,363 · 8
R61$1,005,666 · 1
Top collaborators
- Alysson R. Muotri5 shared
- Alexey V Terskikh5 shared
- Nunzio Bottini4 shared
- Nicholas F. Larusso4 shared
- Ze'Ev A Ronai4 shared
- Kevin Ron Nash2 shared
- Eduard A. Sergienko2 shared
- Lauren M Slosky2 shared
Most similar at Sanford Burnham Prebys Medical Discovery Institute
Same institution · by research overlap
- Charles H Spruck$5,961,722
- Anthony Bruce Pinkerton$3,967,668
Others in their field
Other Emerging Leaders on “In Vivo”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,216,744
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Tony Moody · Duke University$34,777,314
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
Research focus
In VivoLeadSmall MoleculeStructureProteinsDesignMouse ModelReportingPathway InteractionsAlzheimer&AposLead OptimizationNew Therapeutic TargetPharmaceutical PreparationsSignal TransductionPathologicAnalogPharmaceutical ChemistryHigh Throughput ScreeningBrainPre-ClinicalDoseEfficacy StudyInhibitorPharmacology
Grant awards (28)
Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathies$857,439
R01 · FY2025 · AG · contact PI
Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of Cancer$809,248
R01 · FY2025 · CA
Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probes$702,476
R01 · FY2025 · DA
Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathies$878,176
R01 · FY2024 · AG · contact PI
Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of Cancer$809,234
R01 · FY2024 · CA
Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probes$716,226
R01 · FY2024 · DA
GCDH Addiction in Melanoma$401,077
R01 · FY2024 · CA
GCDH Addiction in Melanoma$298,503
R01 · FY2024 · CA
Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathies$894,645
R01 · FY2023 · AG · contact PI
GCDH Addiction in Melanoma$721,672
R01 · FY2023 · CA
Brain pathology and function in a chronic mouse model of ZIKV transmission$654,901
R01 · FY2023 · NS
Targeting neuroinflammation in AD with novel CX3CR1 agonists$554,644
R01 · FY2023 · AG · contact PI
Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathies$942,121
R01 · FY2022 · AG · contact PI
GCDH Addiction in Melanoma$736,400
R01 · FY2022 · CA
Brain pathology and function in a chronic mouse model of ZIKV transmission$655,064
R01 · FY2022 · NS
Targeting neuroinflammation in AD with novel CX3CR1 agonists$562,501
R01 · FY2022 · AG · contact PI
Small molecule inhibitors of LMPTP: an obesity drug target$526,601
R01 · FY2022 · DK
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies$453,913
R01 · FY2022 · DK · contact PI
Small molecule inhibitors of LMPTP: an obesity drug target$1
R01 · FY2022 · DK
Brain pathology and function in a chronic mouse model of ZIKV transmission$655,075
R01 · FY2021 · NS
Small molecule inhibitors of LMPTP: an obesity drug target$497,502
R01 · FY2021 · DK
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies$491,856
R01 · FY2021 · DK · contact PI
IGNITE: Development of novel cyclophilin B/PIKfyve inhibitors for treatment of Malignant Peripheral Nerve Sheath Tumors$1,005,666
R61 · FY2020 · NS · contact PI
Brain pathology and function in a chronic mouse model of ZIKV transmission$654,787
R01 · FY2020 · NS
Small molecule inhibitors of LMPTP: an obesity drug target$500,608
R01 · FY2020 · DK
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies$496,591
R01 · FY2020 · DK · contact PI
Brain pathology and function in a chronic mouse model of ZIKV transmission$678,490
R01 · FY2019 · NS
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies$537,612
R01 · FY2019 · DK · contact PI